Exchange: NASDAQ·Updated 07:30 PM EST
XBIO logo

XBIO Xenetic Biosciences Inc

$1.48
$0.17
(10.24%)
Today
Closed $1.49
$0.01
(0.67%)
After Hours
Mkt Cap$3.89M
Vol17,523.00

About XBIO

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.
42

Bearish Sentiment

How do you feel about XBIO?

Deblitorator
$XBIO Most traders haven't caught on to $XBIO. Their technology is designed to target NETs, which are implicated across multiple cancer types and treatment resistance pathways. Platform biotech + tiny float valuation = serious asymmetric setup when data comes through
1
13
StockfatherOG
$XBIO don’t be surprised to wake up one day with this gapped up 500% with the acquisition catalyst
1
12
StockfatherOG
$XBIO $10 very possible on this bio..load while it’s quiet before it’s too late. The clock is ticking.
14
TheLocoPro
$XBIO who remember when this ran to near $20 in one day around this time last year? Low dilution risk so it can happen again. $DVLT watching dips
13
StockfatherOG
$XBIO has the multi week gapper look. $7M cash vs a $4M MC. Zero debt as well. Should crawl back to the $7-$10 range. $BEAT.X $ROMA $BOOM interest volume today will keep an eye on these .
12
Deblitorator
$XBIO sitting near 52-week lows while fundamentally making progress. Sometimes the best risk/reward setups are where sentiment is washed out but the story keeps improving.
11
DarknessAWAITz
$XBIO = ~$5M market cap, first patient dosed in CAR-T combo study, proprietary NET-targeting cancer platform, and a transformational merger pending. That's a lot of potential packed into a tiny biotech
11
HustlerTV
$XBIO The upcoming transaction with Santerus will create a biotech monster in NET targeting. We got us a mini $MRNA here!
11
GMExAPE
$XBIO trading with only a ~$4-5M market cap while advancing a unique DNase oncology platform targeting NETs, which have been linked to tumor growth, metastasis, and treatment resistance. Tiny valuation for a company attacking a massive cancer market. 👀 🚀$XBIO
11
UnforgivingTrader
$XBIO hearing many say this will pull a much bigger move than $MRNA THE float on $XBIO IS 2M shares va Moderna’s 400M shares..with any news it’s bound to happen..
11
Deblitorator
$XBIO have a good feeling this could 3X from here in the coming weeks.. $TSLA $MSFT $NVDA expect a rally on these tech names around 2.45..warsh effect
10
UnforgivingTrader
$XBIO multi week grinder to $5 (top setup) $ULBI MUST HOLD 15 $BOOM 7.50 break sees $9 $POM $1.80 bounce zone $CHSN BIG WALL @ $1.70
10
HustlerTV
$XBIO by far the best and cheapest biotech I have seen in over a year. Once news hits it will go crazy 🤪
9
UnforgivingTrader
$XBIO too small cap that can see a 300% gain short term. Cleanest setup 💥 $ULBI $CHSN can’t ignore this momentum here added them to my my WL
9
BlockSecurities
$XBIO biotechs with this clean of a structure have the true chance to 5-10X..not saying it will but this one could be the one to do it. Will at least double up from this area.
9
6k_investor
I added $XBIO This is already a fundamentally undervalued play with more cash than their Market Cap and has finally developed support after the selloff and has a Catalyst Coming Any Day Key Catalyst: Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics The Proposed Transaction has been unanimously approved by the Board of Directors of Santersus. Xenetic's Board of Directors - acting on the unanimous recommendation of its independent Special Committee - has also approved the Proposed Transaction and recommends that Xenetic stockholders vote in favor of the Proposed Transaction. The Proposed Transaction is expected to close in the fourth quarter of 2026 The company has 23.4 months of cash left based on quarterly cash burn of -$0.71M and estimated current cash of $5.5M Compared to a $4.2M MC ($7M in total assets compared to less than $1M in Liabilities with NO LONG-TERM DEBT, very rare for a biotech)
9
focafoca99
$XBIO explored a share-exchange deal to form a Nasdaq-listed, NETs-focused clinical-stage company with Santersus.

Advertisement|Remove ads.